Browse the evidence

The healthcare situation for people with obesity in Germany is deficient.

Healthcare providers should recognize the deficiencies in the current obesity care system.

There were previously no legal frameworks for guideline-based care for people with obesity.

Legislators need to establish legal frameworks to support guideline-based obesity care.

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

There was no significant effect of the intervention on daily steps, daily activity energy expenditure, or moderate-to-vigorous physical activity compared to the control group.

Practitioners should note that the program did not significantly increase physical activity levels.

There were no differences in anthropometric variables after the intervention period with strength training.

Strength training may not lead to changes in body composition metrics in this population.

Infertility affects up to 17.5% of the global population.

Awareness of the prevalence of infertility can guide public health initiatives.

The USDA withdrew its Eating Right Pyramid due to pressure from meat and dairy lobbying groups.

Practitioners should be aware of the influence of food lobbying on dietary guidelines.

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend=0.38).

Dietary recommendations regarding white rice may differ in China compared to other regions.

No significant associations were found between GLP-1 receptor agonists or SGLT2 inhibitors and risk of sepsis, abscess, gangrene, or other infections.

Practitioners can be reassured about the lack of infection risk associated with these medications.

Obesity is projected to affect over half of the global population by 2035.

Healthcare providers should prepare for increased obesity-related challenges.

Advances in omics technologies have enabled the identification of molecular subtypes and candidate biomarkers for obesity.

Utilizing omics technologies can enhance personalized approaches to obesity treatment.

The net financial impact to Medicare was estimated to be savings of $715 million over 10 years.

Healthcare policymakers should recognize the potential cost savings associated with semaglutide for Medicare.

Availability of semaglutide in Medicare for all FDA-approved indications would yield net savings ranging from $1.04 billion to $412 million over 10 years.

Healthcare providers should advocate for the inclusion of semaglutide in Medicare to maximize economic and health benefits.

In 2022, 1 in 8 people in the world were living with obesity.

Practitioners should be aware of the significant prevalence of obesity.

Obesity was recognized as a disease by the German Bundestag on July 3, 2020.

This recognition may influence treatment protocols and funding for obesity management.

There is a lack of studies comparing adverse events across different populations for glucagon-like peptide-1 receptor agonists.

Further research is needed to assess the safety of glucagon-like peptide-1 receptor agonists across diverse populations.

Further research is needed to assess the long-term safety of Tirzepatide, particularly regarding cardiovascular outcomes.

Practitioners should be aware of the need for ongoing evaluation of Tirzepatide's long-term safety profile.

Interdisciplinary collaboration and communication between anaesthetists, surgeons, general practitioners, and endocrinologists are required to further investigate and establish preoperative guidelines for safe GLP-1 agonist use.

Healthcare teams should work together to create and follow guidelines for managing patients on GLP-1 agonists in surgical settings.

62% of protein supplement users were male.

Practitioners should note the gender distribution in protein supplement use.

42% of protein supplement users were aged 25–34.

Targeted educational initiatives can be focused on this age group.

Up to half of patients with diabetes mellitus are undiagnosed when referred for elective surgery.

Healthcare providers should consider screening for diabetes in patients scheduled for elective surgery.

The 2015 law for strengthening health promotion and prevention defines goals for T2D.

Legislators and health organizations should be aware of the defined goals for T2D.

The law does not present strategies or financial and personnel prerequisites for effective primary and secondary prevention.

Health policymakers need to develop strategies and allocate resources for effective prevention.

Obesity prevalence is projected to grow by 40% in the next decade.

Health professionals should prepare for increased obesity-related health issues.